5-amino-4-(2,6-dimethyl-4-pyrimidinyl)-2,3-dihydro-1-phenylpyrrol-2-one | 1224936-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 5-amino-4-(2,6-dimethyl-4-pyrimidinyl)-2,3-dihydro-1-phenylpyrrol-2-one
• 英文别名: 5-amino-4-(2,6-dimethylpyrimidin-4-yl)-1-phenyl-3H-pyrrol-2-one
• CAS: 1224936-30-4
• 化学式: C₁₆H₁₆N₄O
• 分子量: 280.329
• InChiKey: BTZLGOVFWWRRAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.16
• 重原子数：
  21.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  72.11
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  2,6-dimethylpyrimidin-4-ylacetonitrile 、 2-氯乙酰苯胺 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 以57%的产率得到5-amino-4-(2,6-dimethyl-4-pyrimidinyl)-2,3-dihydro-1-phenylpyrrol-2-one
  参考文献：
  名称：

  Synthesis of 3-(Pyrimidinyl)pyrrole Derivatives

  摘要：

  Alkylation of 4,6-dimethy1-2-pyrimidineacetonitrile and 2,6-dimethyl-4-pyrimidineacetonitrile with chloroacetic acid anilides was shown to give 5-amino-4-(4,6-dimethyl-2-pyrimidinyl)-2,3-dihydro-1-arylpyrrol-2-ones and 5-amino-4-(2,6-dimethyl-4-pyrimidinyl)-2,3-dihydro-1-arylpyrrol-2-ones, respectively. Corresponding isomeric compounds, 5-amino-4-pyrimidinyl-2,3-dihydropyrrol-3-ones were obtained by Claisen condensation of the mentioned pyrimidineacetonitriles with N-Boc alpha-aminoacids imidazolides followed by removal of the protecting group accompanied with simultaneous ring closure.

  DOI：

  10.3987/com-09-11881

文献信息

• Synthesis of 3-(Pyrimidinyl)pyrrole Derivatives
  作者：Anton V. Tverdokhlebov、Igor Yu. Nestorak、Andrey A. Tolmachev、Yulian M. Volovenko

  DOI：10.3987/com-09-11881

  日期：——

  Alkylation of 4,6-dimethy1-2-pyrimidineacetonitrile and 2,6-dimethyl-4-pyrimidineacetonitrile with chloroacetic acid anilides was shown to give 5-amino-4-(4,6-dimethyl-2-pyrimidinyl)-2,3-dihydro-1-arylpyrrol-2-ones and 5-amino-4-(2,6-dimethyl-4-pyrimidinyl)-2,3-dihydro-1-arylpyrrol-2-ones, respectively. Corresponding isomeric compounds, 5-amino-4-pyrimidinyl-2,3-dihydropyrrol-3-ones were obtained by Claisen condensation of the mentioned pyrimidineacetonitriles with N-Boc alpha-aminoacids imidazolides followed by removal of the protecting group accompanied with simultaneous ring closure.